Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone
Status:
RECRUITING
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
To study intrasubject variability and steady-state pharmacokinetics of multiple-doses of Extended Release Torsemide and Spironolactone Fixed Dose Combination (FDC) tablets given together in healthy adult subjects.